Original Article
Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age
N Engl J Med 2008; 359:2521-2532December 11, 2008
- Abstract
Background
Plasmodium falciparum malaria is a pressing global health problem. A previous study of the malaria vaccine RTS,S (which targets the circumsporozoite protein), given with an adjuvant system (AS02A), showed a 30% rate of protection against clinical malaria in children 1 to 4 years of age. We evaluated the efficacy of RTS,S given with a more immunogenic adjuvant system (AS01E) in children 5 to 17 months of age, a target population for vaccine licensure.
Methods
We conducted a double-blind, randomized trial of RTS,S/AS01E vaccine as compared with rabies vaccine in children in Kilifi, Kenya, and Korogwe, Tanzania. The primary end point was fever with a falciparum parasitemia density of more than 2500 parasites per microliter, and the mean duration of follow-up was 7.9 months (range, 4.5 to 10.5).
Results
A total of 894 children were randomly assigned to receive the RTS,S/AS01E vaccine or the control (rabies) vaccine. Among the 809 children who completed the study procedures according to the protocol, the cumulative number in whom clinical malaria developed was 32 of 402 assigned to receive RTS,S/AS01E and 66 of 407 assigned to receive the rabies vaccine; the adjusted efficacy rate for RTS,S/AS01E was 53% (95% confidence interval [CI], 28 to 69; P<0.001) on the basis of Cox regression. Overall, there were 38 episodes of clinical malaria among recipients of RTS,S/AS01E, as compared with 86 episodes among recipients of the rabies vaccine, with an adjusted rate of efficacy against all malarial episodes of 56% (95% CI, 31 to 72; P<0.001). All 894 children were included in the intention-to-treat analysis, which showed an unadjusted efficacy rate of 49% (95% CI, 26 to 65; P<0.001). There were fewer serious adverse events among recipients of RTS,S/AS01E, and this reduction was not only due to a difference in the number of admissions directly attributable to malaria.
Conclusions
RTS,S/AS01E shows promise as a candidate malaria vaccine. (ClinicalTrials.gov number, NCT00380393.)
Media in This Article
Figure 1
Screening, Randomization, and Follow-up of Study Participants.Figure 2
Kaplan–Meier Estimates of the Time to the First or Only Episode of Clinical Malaria.Article Activity
- Article
Worldwide, the mortality and morbidity associated with Plasmodium falciparum malaria are high.1-3 Progress has been made in controlling malaria by introducing insecticide-treated nets4 and highly effective artemisinin-based combination treatments.5 There is evidence that the incidence of malaria is falling in some areas.6-10 These advances have renewed interest in the prospects for the control of malaria and even its elimination in areas in which P. falciparum was previously endemic.11 A safe and affordable vaccine providing protection against malaria would be an important addition to control strategies and should be assessed in the context of the use of insecticide-treated nets and the availability of artemisinin-based combination treatments.
The candidate pre-erythrocytic malaria vaccine RTS,S targets the circumsporozoite protein and has been evaluated in combination with two different adjuvant systems: AS01 and AS02. Clinical development of RTS,S in field trials began with the AS02 adjuvant system. Preliminary estimates of rates of efficacy against infection after curative antimalarial treatment were 34% (95% confidence interval [CI], 8 to 53) in adults12 and 66% (95% CI, 43 to 80) in infants.13 The rate of efficacy against the more clinically relevant end point of clinical malaria in children 1 to 4 years of age was 30% (95% CI, 11 to 45).14
Planning is now under way for a multicenter phase 3 trial. However, since preliminary data suggested better immunogenicity with the AS01 adjuvant,15-17 there was a need to evaluate RTS,S administered with the AS01 adjuvant system before selecting the vaccine formulation for phase 3. We evaluated the efficacy of RTS,S/AS01E against clinical malaria in children 5 to 17 months of age.
Methods
Study Design
The study was randomized, controlled, and double-blind and was prospectively registered at ClinicalTrials.gov. Approval was obtained from the Kenyan Medical Research Institute National Ethics Committee, the Tanzanian Medical Research Coordinating Committee, the Central Oxford Research Ethics Committee, the London School of Hygiene and Tropical Medicine Ethics Committee, and the Western Institutional Review Board in Seattle. An independent data and safety monitoring board and local safety monitors were appointed. The study was conducted in accordance with the Helsinki Declaration of 1964 (revised in 1996) and according to Good Clinical Practice guidelines.
GlaxoSmithKline Biologicals was the study sponsor. The database was managed by the sponsor and was opened to the principal investigators at the time of unblinding. Analysis was performed in parallel by an industry author who is an employee of the sponsor and an academic author. Two academic authors and the industry author vouch for the data and analysis. The first draft of the manuscript was written by an academic author, who subsequently implemented revisions from all the authors after their review.
GlaxoSmithKline and both study sites (Kilifi, Kenya, and Korogwe, Tanzania) received funding to undertake the work described in this report from the Program for Appropriate Technology in Health (PATH) Malaria Vaccine Initiative (MVI), which was involved in all aspects of the study design. Permission to submit the manuscript for publication was given by the directors of the Kenya Medical Research Institute and the National Institute for Medical Research of Tanzania. More details of the investigators' and sponsor's roles in the study are given in the Supplementary Appendix, available with the full text of this article at www.nejm.org.
Study Participants
We randomly assigned children to receive either the candidate malaria vaccine or a licensed rabies vaccine in a 1:1 ratio at the two study sites (for more details, see the Supplementary Appendix). Vaccinations took place over a 6-month period from March through August 2007. Active surveillance for malaria began 2.5 months after the first vaccination and continued throughout the follow-up period. Venous-blood samples were taken to screen for eligibility, 3 months after the first vaccination as well as in March 2008 (irrespective of the time of recruitment). The study was unblinded at the time of the final blood test, in March 2008. Hence, the duration of follow-up varied according to the time of recruitment, between 4.5 and 10.5 months (mean, 7.9). A locked database containing data collected through the time of the final blood test was unblinded and the data were analyzed in August 2008. The database of adverse events collected up to August 4, 2008, was locked, and the data were analyzed in August 2008.
The participating children were 5 to 17 months of age at the time of the first vaccination, were healthy, and were residents of the study area. Details of the screening are given in the Supplementary Appendix. Written informed consent in an appropriate language (Swahili, Chonyi, or Giriama) was obtained from each child's parent (or parents) or guardian before the study procedures were initiated. Nonliterate parents indicated consent using a thumbprint, and a signature was obtained from a literate witness.
Vaccines
Children were randomly assigned to receive three doses of RTS,S/AS01E or three doses of a human diploid-cell rabies vaccine (rabies vaccine BP, Sanofi-Pasteur). Both vaccines were administered intramuscularly in the deltoid, with one dose given each month for 3 months. Further details about the vaccines are given in the Supplementary Appendix.
Randomization and Vaccination
The RTS,S/AS01E and rabies vaccines were packaged in identical boxes labeled with treatment numbers from a randomization list generated at GlaxoSmithKline Biologicals in Rixensart, Belgium, and then shipped to the trial sites. Block randomization was used, with stratification according to study site. Subjects were assigned treatment numbers on the basis of order of attendance at the clinic. Boxes containing the assigned vaccine were opened out of sight of the investigators who evaluated the study end points, the study subjects, and their parents or guardians. The syringe used to draw up the vaccine was masked. Personnel preparing the vaccines were aware of the treatment assignments but took no other part in study-related procedures and were instructed not to reveal the assignments to either the parents or guardians of the study subjects or the investigators.
Monitoring for Episodes of Clinical Malaria
The primary end point was a clinical episode of malaria, defined as an axillary temperature of 37.5°C or higher with a P. falciparum density of more than 2500 parasites per microliter. The presence of any falciparum parasitemia density with a temperature of 37.5°C or higher was a secondary end point.
Active surveillance was performed through weekly visits by field-workers to the home to identify febrile children. Passive surveillance was performed by field-workers and by personnel in the local health facilities. Further details of these visits, as well as safety assessments and laboratory methods, are described in the Supplementary Appendix. The implementation of active surveillance was unintentionally delayed by 3 months in Korogwe, but passive surveillance was conducted during this period.
Statistical Analysis
The study was designed to have a statistical power of 90% to detect a 30% efficacy rate, at a significance level of 0.05, based on a projected malaria incidence of 36% among children receiving the rabies-vaccine doses during a 4-month surveillance period. This design required 800 subjects who could be evaluated, with a total enrollment of 890 subjects to allow for loss to follow-up. Before the beginning of the study, it was planned that the number of episodes of clinical malaria would be monitored in real time and that unblinding of the data would be delayed if fewer than 245 episodes had been recorded by the time this number was reached. In fact, the rates of malaria were considerably lower than expected. The unblinding was delayed, but by the time the transmission season was ending, just over 100 episodes had been recorded. We believed that the target of 245 episodes would not be reached in the near future, and the trial was therefore unblinded on August 4, 2008, after discussion among the investigators, sponsors, regulatory authorities, and data and safety monitoring board.
An analysis plan was agreed on by the data and safety monitoring board, sponsor, and investigators before the unblinding. The primary analysis was an estimate of the hazard ratio for the first or only episode of malaria involving fever and a parasite density above 2500 per microliter (the primary end point) for the group that received the RTS,S/AS01E vaccine as compared with the control group in the according-to-protocol cohort. Secondary analyses included episodes of malaria involving any parasitemia density with fever (a secondary end point) in the according-to-protocol cohort, as well as cases qualifying as primary and secondary end points in the intention-to-treat cohort (i.e., all children randomly assigned to receive vaccinations) and multiple episodes of malaria (analyzed by means of Poisson regression). The period for the according-to-protocol analysis was 2 weeks after the last vaccination until the final blood test. The period for the intention-to-treat analysis was the time from the first vaccination until the final blood test. More details are given in the Supplementary Appendix.
The effect of anticircumsporozoite antibodies on the risk of clinical malaria was examined with the use of titers measured 1 month after the third dose. Log-transformed titers (with undetectable levels scored as a value that was half the lower limit of detection) were used as a continuous variable in an adjusted Cox regression analysis for the children receiving the RTS,S/AS01E vaccine.
Safety data are presented for the intention-to-treat cohort, and efficacy data are presented for both the according-to-protocol cohort and the intention-to-treat cohort. Data were analyzed from the time of the first vaccination until the time of the final blood test for efficacy, but all the available safety data up to August 4, 2008 (the time of unblinding), were analyzed. Serious adverse events are described with the use of the preferred terms from the Medical Dictionary for Regulatory Activities (MedDRA).18
Results
A total of 1162 children were screened; 894 were randomly assigned to a study group and received at least one vaccination, and data for 809 were included in the according-to-protocol analysis of efficacy (Figure 1Figure 1
Screening, Randomization, and Follow-up of Study Participants.). The demographic characteristics of the participants were balanced between the two vaccine groups (Table 1Table 1
Baseline Characteristics of the Subjects, According to Vaccine Group.).Efficacy
In the according-to-protocol analysis (of data over a mean of 8 months of follow-up, beginning 2 weeks after the final vaccination), the cumulative incidence of the first or only malarial episode, as defined for the primary end point, was 8% (32 of 402 subjects) in the group that received the RTS,S/AS01E vaccine, as compared with 16% (66 of 407 subjects) in the group that received the rabies vaccine. Cox regression provided an adjusted efficacy of 53% (95% CI, 28 to 69; P<0.001) and an unadjusted efficacy of 55% (95% CI, 31 to 70; P<0.001) (Figure 2Figure 2
Kaplan–Meier Estimates of the Time to the First or Only Episode of Clinical Malaria.). In the intention-to-treat analysis (of data collected over a mean of 10.5 months of follow-up, beginning with the first vaccination), the cumulative incidence of the first or only episode meeting the criteria for the primary end point was 9% (42 of 447 subjects) in the group receiving the RTS,S/AS01E vaccine and 17% (78 of 447) in the group receiving the rabies vaccine, with an unadjusted efficacy rate of 49% (95% CI, 26 to 65; P<0.001) on the basis of Cox regression.
In the according-to-protocol analysis, 6 of 402 subjects in the RTS,S/AS01E group (1%) and 14 of 407 subjects in the rabies-vaccine group (3%) had more than one episode of clinical malaria. In the intention-to-treat analysis, 6 of the 447 subjects in the RTS,S/AS01E group (1%) and 17 of 447 in the rabies-vaccine group (4%) had more than one clinical episode. The rate of efficacy against all clinical episodes meeting the criteria for the primary end point was 56% (95% CI, 31 to 72; P<0.001) for the RTS,S/AS01E vaccine on the basis of Poisson regression, which was similar to the rate of efficacy against first or only episodes. The results of the intention-to-treat analysis were similar (Table 2Table 2
Efficacy of the RTS,S/AS01E Vaccine against Episodes of Clinical Malaria.).Estimates of efficacy according to the secondary end point of fever with any P. falciparum parasitemia density were similar to those according to the primary end point (Table 2). Two cases of parasitemia were identified in the rabies-vaccine group when clinicians, responding to the concerns of the parents, believed a malaria test was warranted despite the absence of fever. Including these two cases did not change the results appreciably. Estimates of efficacy were similar at each site (in Kilifi, 55%; 95% CI, 25 to 73; P=0.002; and in Korogwe, 56%; 95% CI, 4 to 80; P=0.04).
Asymptomatic parasitemia was detected infrequently at the time of the final blood test (in 2% of subjects in the RTS,S/AS01E group and 3% of those in the rabies-vaccine group), and the mean hemoglobin level was similar in the two vaccine groups (10.3 g per deciliter and 10.4 g per deciliter, respectively; P=0.22).
Safety
In all, 47 of the 447 children receiving the RTS,S/AS01E vaccine had one or more serious adverse events (11%; 95% CI, 8 to 14), as did 82 of the 447 children receiving the rabies vaccine (18%; 95% CI, 15 to 22). The lower rate of serious adverse events in the RTS,S/AS01E group was only partly accounted for by a reduction in admissions related to falciparum malaria. A total of 51 MedDRA-preferred terms were used to describe the serious adverse events. The numbers of children with the three most common diagnoses and those with serious adverse events not related to malaria are shown according to vaccine group in Table 3Table 3
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) in the Intention-to-Treat Cohort, According to the Vaccine Group.. Less-common serious adverse events (those occurring fewer than 10 times per group) are not shown, but there was no obvious imbalance between the two groups in the rates of these events. Laboratory safety tests did not reveal any significant difference in the frequency of out-of-range values between the two treatment groups. No out-of-range values were considered to be related to vaccination.Between the time of the first vaccination and the time of unblinding, one episode in the RTS,S/AS01E group met the criteria for severe malaria, as compared with eight episodes of severe malaria among seven children in the rabies-vaccine group. Of the children with severe malaria, two had cerebral malaria, one had severe anemia, and the remaining five had other types of severe malaria (defined in the Supplementary Appendix). All children treated for acute malarial infection recovered without sequelae.
One serious adverse event was judged to be related to vaccine: a simple febrile seizure, observed 1 day after vaccination with RTS,S/AS01E. The seizure terminated spontaneously, and there were no neurologic abnormalities detected 24 hours afterward. Despite the facilitated access to medical care during the study, two children died (one at home and one while being brought to the dispensary), with no clinical evaluation. One child, who had been vaccinated 9 months earlier with RTS,S/AS01E, had generalized convulsions and loss of consciousness. Traditional medicine was used, but the child died without being brought to the health center. The other child, who had been given the rabies vaccine and was subsequently withdrawn from the study because of the parents' anxiety about the blood sampling, had atypical prolonged seizures, lost consciousness, and died while being brought to the health center. Neither death was judged to be related to the study vaccine.
The frequency of local adverse events during the first 7 days after each of the three vaccinations is shown in Table 3. Unsolicited adverse events (those reported by parents spontaneously rather than in response to questions from field-workers) occurring in more than 5% of children per group are also shown. Unsolicited symptoms were recorded during the first 30 days. These were classified according to the MedDRA-preferred term, and 105 preferred terms were assigned. There was no obvious imbalance between the two vaccine groups with respect to these other, less-frequent adverse events, and all were expected events for the population. A total of 77% of children in the RTS,S/AS01E group and 76% of those in the rabies-vaccine group had unsolicited adverse events that were not related to malaria.
Immunogenicity
The geometric mean titer of anticircumsporozoite antibody 1 month after the third vaccination was 539.6 enzyme-linked immunosorbent assay units (EU) per milliliter (95% CI, 500.7 to 581.6) in the RTS,S/AS01E group, as compared with 0.3 EU per milliliter (95% CI, 0.3 to 0.3) in the rabies-vaccine group (with a limit of detection of 0.5 EU per milliliter). The geometric mean titer in the RTS,S/AS01E group had fallen by the time of the final cross-sectional survey at 4.5 to 10.5 months (71.9 EU per milliliter; 95% CI, 66 to 79) but remained higher than in the rabies-vaccine group (0.3 EU per milliliter; 95% CI, 0.2 to 0.3).
There was a wide range of antibody titers after vaccination (Figure 3Figure 3
Time Course of Anticircumsporozoite Antibody Titers for the According-to-Protocol Cohort, According to Vaccination Group.), but more than 99% of the children in the RTS,S/AS01E group had detectable anticircumsporozoite titers. There was no evidence that RTS,S/AS01E-vaccinated children with high titers had greater protection against clinical disease than those with lower titers. Each increase by a factor of 10 in the anticircumsporozoite antibody titer (assessed 1 month after the third dose) was associated with an increase in efficacy of 9% (95% CI, −25 to 34; P=0.58).All children had received the usual course of hepatitis B vaccine, with doses at 6, 10, and 14 weeks of age; the prevalence of hepatitis B virus surface antibody titers above 10 mIU per milliliter was 97% at screening and 100% one month after the third RTS,S/AS01E vaccination. There was no correlation between the hepatitis B virus surface antibody titer at screening and the circumsporozoite titer after vaccination (r=0.06, P=0.21), but there was a strong correlation between the hepatitis B virus surface antibody titer at screening and the titer after vaccination (r=0.48, P<0.001).
Discussion
The RTS,S/AS01E malaria vaccine has significant efficacy against clinical malaria in the field in a target group for licensure (i.e., children 5 to 17 months of age). Our estimate of efficacy against clinical malaria for RTS,S given with the AS01 adjuvant system is higher than previous estimates with the use of the AS02 adjuvant system.14 AS01 is a more immunogenic adjuvant than AS02 in comparative studies.15-17 The mean antibody titer in our study (539.6 EU per milliliter; 95% CI, 500.7 to 581.6) was higher than the antibody titers induced by RTS,S/AS02D in young infants (199.9 EU per milliliter; 95% CI, 150.9 to 264.7)13 and in children 1 to 4 years of age (158 EU per milliliter; 95% CI, 142 to 176).14 The antibody titer was 40 EU per milliliter (95% CI, 36 to 45) 6 months after vaccination with RTS,S/AS02D, but in our study, the titer was 71.9 EU per milliliter (95% CI, 65.7 to 78.6) 4.5 to 10.5 months (mean, 8) after vaccination with RTS,S/AS01E.
However, there are other differences between the studies. The intensity of malaria transmission is falling on the East African coast, probably as a result of increasing use of insecticide-treated nets.6,7 We used active and passive case detection rather than passive case detection alone and studied a younger group of children than those in Mozambique.14 In Mozambique, there was 47% efficacy against clinical malaria among children under 2 years of age, as compared with 30% overall efficacy among children 1 to 4 years of age, albeit with wide confidence intervals (15 to 67%) and without a significant interaction between age and vaccine efficacy. Whatever the explanation for the higher efficacy and immunogenicity, our data support the conduct of a phase 3 trial of RTS,S/AS01E.
We detected fewer serious adverse events in children receiving the RTS,S/AS01E vaccine than in children receiving the rabies vaccine. Although previous studies have shown a reduced rate of serious adverse events in children vaccinated with RTS,S/AS02A,19 our results suggest that not all of this reduction is directly attributable to malaria. This raises the possibility that preventing malaria through vaccination may have indirect as well as direct effects. Some trials have suggested indirect effects of the use of insecticide-treated nets,20 but this has not been confirmed in other studies.21 Indirect effects of malaria might be more likely to result from chronic parasitemia than from the acute, promptly treated episodes seen in our cohort,22 although a decreased rate of growth in children after an acute episode has also been observed.23 The possible indirect benefits of vaccination will be examined further in a phase 3 multicenter trial.
The immunologic correlate of protection remains unknown. Antibodies13 and cell-mediated immunity24,25 have been associated with protection against infection, but not against clinical disease,14 in previous studies. We found no correlation between the anticircumsporozoite antibody titer and protection against clinical disease in this study, despite the wide variation in anticircumsporozoite antibody responses among the vaccinated children. This result does not rule out a role for anticircumsporozoite antibody responses. For instance, in studies of immunity to blood-stage parasites, the functional properties of antibodies, but not the overall titer, determine the outcome.26 Studies of cell-mediated immunity in this cohort are still under way.
There was a 3-month delay in implementing active case detection at one site in our study, accounting for 87 person-years at risk out of a total of 491 person-years at risk for the two sites. During this period, passive case detection was implemented, and transmission appeared to be low (with identification of <25% of the total cases). Furthermore, during the rest of the study, 92% of malarial episodes were detected through passive rather than active case detection, and estimates of efficacy were similar at the two sites. Hence, it seems unlikely that a large number of cases were missed. Our findings indicate that the RTS,S/AS01E vaccine should be further tested in a phase 3, multicenter trial.
Supported by grants from the PATH Malaria Vaccine Initiative (MVI) and GlaxoSmithKline Biologicals.
Dr. Leach, Mr. Lievens, Dr. Vekemans, Ms. Dubois, Dr. Demoitié, Mr. Stallaert, and Dr. Cohen report being employees of GlaxoSmithKline Biologicals; Dr. Ballou reports having been an employee during the design and implementation of the study but reports becoming an employee of the Bill and Melinda Gates Foundation by the time the results were available. Dr. Leach, Dr. Gould, Ms. Dubois, Dr. Ballou, and Dr. Cohen report owning shares in GlaxoSmithKline. Drs. Ballou and Cohen report being listed as inventors of patented malaria vaccines. Ms. Vansadia, Mr. Carter, Ms. Savarese, and Dr. Villafana report being employees of MVI, which supports the development and testing of several malaria vaccines. Prof. Marsh reports receiving grant support from the Wellcome Trust.
No other potential conflict of interest relevant to this article was reported.
This article (10.1056/NEJMoa0807381) was published on December 8, 2008, and updated on October 27, 2010, at NEJM.org.
We thank the participants and their parents and the village and district authorities for their cooperation; the data and safety monitoring board, chaired by Prof. Malcolm Molyneux, and the local safety monitors, Dr. Jay Berkley in Kilifi and Dr. Firimina Mberesero in Korogwe; Prof. Raimos Olomi for supervising pediatric care in Korogwe; Anna Randall, Denise Dekker, James Beard, Roly Gosling, and Hugh Reyburn for providing support in Korogwe; Thor Theander and Brian Greenwood for helping to set up the Joint Malaria Programme collaboration, and Brian Greenwood for advice regarding the design and execution of the trial; Dr. Norbert Peshu (unit director), Edna Ogada, Tabitha Mwangi, Jacinta Mutegi (site coordinator), and Dorothy Mwachiro (community liaison officer) for providing support in Kilifi; and the staff of the Malaria Project Team at GlaxoSmithKline — in particular, Nathalie Annez, Delphine Beauport, Sarah Benns (professional writer), Conor Cahill (professional writer), Philippe Dehottay, Issam Jaimai, Philippe Moris, Sarah Muthuri, Ezekiel Oenga, Opokua Ofori Anyinam, Srilakshmi Pranesh, Isabelle Ramboer, Marie-Sylvie Remacle (professional writer), Christine Swysen, Joelle Thonnard, Marie Chantal Uwamwezi, Wendy Valinski, and Laurence Vigneron.
Source Information
From the Centre for Geographic Medicine Research (Coast), Kenya Medical Research Institute, Kilifi, Kenya (P.B., A.O., T.L., P.N., K.O.A., N.M., K.M.); the Centre for Clinical Vaccinology and Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom (P.B., K.M.); the National Institute for Medical Research, Tanga Centre (J.L., S.M., A.M., O.A., S.G., M.M.L.), and the Joint Malaria Programme, Korogwe (J.L., S.M., J.G., A.M., O.A., S.G., C.J.D., E.M.R., M.M.L., L.S.) — both in Tanzania; Centre for Medical Parasitology, University of Copenhagen, Denmark (J.L.); GlaxoSmithKline Biologicals, Rixensart, Belgium (A.L., M.L., J.V., M.-C.D., M.-A.D., J.-F.S., W.R.B., J.C.); the London School of Hygiene and Tropical Medicine, London (J.G., C.J.D., E.M.R., L.S.); Program for Appropriate Technology in Health (PATH) Malaria Vaccine Initiative, Bethesda, MD (P.V., T.C., B.S., T.V.); the International Vaccine Institute, Seoul, Korea (L.S.); and the Mahidol Oxford Research Unit, Bangkok, Thailand (L.S.).
Address reprint requests to Dr. Bejon at KEMRI, P.O. Box 230, Mombasa, Kenya, or at pbejon@kilifi.kemri-wellcome.org.
- References
References
1
Snow RW ,Guerra CA ,Noor AM ,Myint HY ,Hay SI . The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005;434:214-217
CrossRef | Web of Science | Medline2
Hay SI ,Guerra CA ,Tatem AJ ,Noor AM ,Snow RW . The global distribution and population at risk of malaria: past, present, and future. Lancet Infect Dis 2004;4:327-336
CrossRef | Web of Science | Medline3
Snow RW ,Craig M ,Deichmann U ,Marsh K . Estimating mortality, morbidity and disability due to malaria among Africa's non-pregnant population. Bull World Health Organ 1999;77:624-640
Web of Science | Medline4
Lengeler C . Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev 2004;2:CD000363-CD000363
Medline5
Nosten F ,White NJ . Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 2007;77:Suppl 6:181-192
Web of Science | Medline6
Okiro EA ,Hay SI ,Gikandi PW , et al. The decline in paediatric malaria admissions on the coast of Kenya. Malar J 2007;6:151-151
CrossRef | Web of Science | Medline7
O'Meara WP ,Mwangi TW ,Williams TN ,McKenzie FE ,Snow RW ,Marsh K . Relationship between exposure, clinical malaria, and age in an area of changing transmission intensity. Am J Trop Med Hyg 2008;79:185-191
Web of Science | Medline8
Barnes KI ,Durrheim DN ,Little F , et al. Effect of artemether-lumefantrine policy and improved vector control on malaria burden in KwaZulu-Natal, South Africa. PLoS Med 2005;2:e330-e330
CrossRef | Web of Science | Medline9
Bhattarai A ,Ali AS ,Kachur SP , et al. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med 2007;4:e309-e309
CrossRef | Web of Science | Medline10
Nyarango PM ,Gebremeskel T ,Mebrahtu G , et al. A steep decline of malaria morbidity and mortality trends in Eritrea between 2000 and 2004: the effect of combination of control methods. Malar J 2006;5:33-33
CrossRef | Web of Science | Medline11
Greenwood BM ,Fidock DA ,Kyle DE , et al. Malaria: progress, perils, and prospects for eradication. J Clin Invest 2008;118:1266-1276
CrossRef | Web of Science | Medline12
Bojang KA ,Milligan PJ ,Pinder M , et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001;358:1927-1934
CrossRef | Web of Science | Medline13
Aponte JJ ,Aide P ,Renom M , et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 2007;370:1543-1551
CrossRef | Web of Science | Medline14
Alonso PL ,Sacarlal J ,Aponte JJ , et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004;364:1411-1420
CrossRef | Web of Science | Medline15
Garcon N ,Chomez P ,Van Mechelen M . GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007;6:723-739
CrossRef | Web of Science | Medline16
Mettens P ,Dubois PM ,Demoitie MA , et al. Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen. Vaccine 2008;26:1072-1082
CrossRef | Web of Science | Medline17
Stewart VA ,McGrath SM ,Dubois PM , et al. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect Immun 2007;75:2283-2290
CrossRef | Web of Science | Medline18
MedDRA, version 11.1. Geneva: International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH), 2008.
19
Alonso PL ,Sacarlal J ,Aponte JJ , et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 2005;366:2012-2018
CrossRef | Web of Science | Medline20
Binka FN ,Hodgson A ,Adjuik M ,Smith T . Mortality in a seven-and-a-half-year follow-up of a trial of insecticide-treated mosquito nets in Ghana. Trans R Soc Trop Med Hyg 2002;96:597-599
CrossRef | Web of Science | Medline21
Nevill CG ,Some ES , Mung`ala VO, et al. Insecticide-treated bednets reduce mortality and severe morbidity from malaria among children on the Kenyan coast. Trop Med Int Health 1996;1:139-146
CrossRef | Web of Science | Medline22
Snow RW ,Korenromp EL ,Gouws E . Pediatric mortality in Africa: Plasmodium falciparum malaria as a cause or risk? Am J Trop Med Hyg 2004;71:Suppl 2:16-24
Web of Science | Medline23
Nyakeriga AM ,Troye-Blomberg M ,Chemtai AK ,Marsh K ,Williams TN . Malaria and nutritional status in children living on the coast of Kenya. Am J Clin Nutr 2004;80:1604-1610
Web of Science | Medline24
Sun P ,Schwenk R ,White K , et al. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma. J Immunol 2003;171:6961-6967
Web of Science | Medline25
Reece WH ,Pinder M ,Gothard PK , et al. A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease. Nat Med 2004;10:406-410
CrossRef | Web of Science | Medline26
Okech BA ,Corran PH ,Todd J , et al. Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia. Infect Immun 2004;72:1557-1567
CrossRef | Web of Science | Medline
- Citing Articles (102)
Citing Articles
1
Noah S. Butler, Ashley M. Vaughan, John T. Harty, Stefan H.I. Kappe. (2012) Whole parasite vaccination approaches for prevention of malaria infection. Trends in Immunology 33:5, 247-254
CrossRef2
Ashley M Vaughan, Stefan HI Kappe. (2012) Malaria vaccine development: persistent challenges. Current Opinion in Immunology
CrossRef3
Gisela Kynast-Wolf, Wieda Wakilzadeh, Boubacar Coulibaly, Paul Schnitzler, Corneille Traoré, Heiko Becher, Olaf Müller. (2012) ITN protection, MSP1 antibody levels and malaria episodes in young children of rural Burkina Faso. Acta Tropica
CrossRef4
Mahamadou A. Thera, Christopher V. Plowe. (2012) Vaccines for Malaria: How Close Are We?. Annual Review of Medicine 63:1, 345-357
CrossRef5
D. Lys Guilbride, Patrick D.L. Guilbride, Pawel Gawlinski. (2012) Malaria's deadly secret: a skin stage. Trends in Parasitology
CrossRef6
D. S. Yamamoto, M. Sumitani, H. Nagumo, S. Yoshida, H. Matsuoka. (2012) Induction of antisporozoite antibodies by biting of transgenic Anopheles stephensi delivering malarial antigen via blood feeding. Insect Molecular Biologyno-no
CrossRef7
(2011) Mixed results for a malaria vaccine. Nature Medicine 17:12, 1560-1561
CrossRef8
T.A. Lang, J. Gould, L. von Seidlein, J.P. Lusingu, S. Mshamu, S. Ismael, E. Liheluka, D. Kamuya, D. Mwachiro, A. Olotu, P. Njuguna, P. Bejon, V. Marsh, C. Molyneux. (2011) Approaching the community about screening children for a multicentre malaria vaccine trial. International Health
CrossRef9
U. Heininger, N.S. Bachtiar, P. Bahri, A. Dana, A. Dodoo, J. Gidudu, E. Matos dos Santos. (2011) The concept of vaccination failure. Vaccine
CrossRef10
G.J.V. Nossal. (2011) Vaccines of the future. Vaccine 29, D111-D115
CrossRef11
White, Nicholas J., . (2011) A Vaccine for Malaria. New England Journal of Medicine 365:20, 1926-1927
Full Text12
The RTS,S Clinical Trials Partnership. (2011) First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children. New England Journal of Medicine 365:20, 1863-1875
Full Text13
K.O. Okosun, Rachid Ouifki, Nizar Marcus. (2011) Optimal control analysis of a malaria disease transmission model that includes treatment and vaccination with waning immunity. Biosystems 106:2-3, 136-145
CrossRef14
Lin H Chen, David R Hill, Annelies Wilder-Smith. (2011) Vaccination of travelers: how far have we come and where are we going?. Expert Review of Vaccines 10:11, 1609-1620
CrossRef15
G. J. V. Nossal. (2011) Vaccines and future global health needs. Philosophical Transactions of the Royal Society B: Biological Sciences 366:1579, 2833-2840
CrossRef16
A. V. S. Hill. (2011) Vaccines against malaria. Philosophical Transactions of the Royal Society B: Biological Sciences 366:1579, 2806-2814
CrossRef17
Alassane Dicko, Ogobara Doumbo. (2011) Efficacy of RTS,S malaria vaccine given with EPI vaccines. The Lancet Infectious Diseases 11:10, 722-723
CrossRef18
Kwaku Poku Asante, Salim Abdulla, Selidji Agnandji, John Lyimo, Johan Vekemans, Solange Soulanoudjingar, Ruth Owusu, Mwanajaa Shomari, Amanda Leach, Erik Jongert, Nahya Salim, Jose F Fernandes, David Dosoo, Maria Chikawe, Saadou Issifou, Kingsley Osei-Kwakye, Marc Lievens, Maria Paricek, Tina Möller, Stephen Apanga, Grace Mwangoka, Marie-Claude Dubois, Tigani Madi, Evans Kwara, Rose Minja, Aurore B Hounkpatin, Owusu Boahen, Kingsley Kayan, George Adjei, Daniel Chandramohan, Terrell Carter, Preeti Vansadia, Marla Sillman, Barbara Savarese, Christian Loucq, Didier Lapierre, Brian Greenwood, Joe Cohen, Peter Kremsner, Seth Owusu-Agyei, Marcel Tanner, Bertrand Lell. (2011) Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. The Lancet Infectious Diseases 11:10, 741-749
CrossRef19
Xinyuan Chen, Mei X Wu. (2011) Laser vaccine adjuvant for cutaneous immunization. Expert Review of Vaccines 10:10, 1397-1403
CrossRef20
Thera, Mahamadou A., Doumbo, Ogobara K., Coulibaly, Drissa, Laurens, Matthew B., Ouattara, Amed, Kone, Abdoulaye K., Guindo, Ando B., Traore, Karim, Traore, Idrissa, Kouriba, Bourema, Diallo, Dapa A., Diarra, Issa, Daou, Modibo, Dolo, Amagana, Tolo, Youssouf, Sissoko, Mahamadou S., Niangaly, Amadou, Sissoko, Mady, Takala-Harrison, Shannon, Lyke, Kirsten E., Wu, Yukun, Blackwelder, William C., Godeaux, Olivier, Vekemans, Johan, Dubois, Marie-Claude, Ballou, W. Ripley, Cohen, Joe, Thompson, Darby, Dube, Tina, Soisson, Lorraine, Diggs, Carter L., House, Brent, Lanar, David E., Dutta, Sheetij, Heppner, D. Gray Jr., Plowe, Christopher V., . (2011) A Field Trial to Assess a Blood-Stage Malaria Vaccine. New England Journal of Medicine 365:11, 1004-1013
Full Text21
Jennifer D Bassett, Stephanie L Swift, Jonathan L Bramson. (2011) Optimizing vaccine-induced CD8 + T-cell immunity: focus on recombinant adenovirus vectors. Expert Review of Vaccines 10:9, 1307-1319
CrossRef22
Lawrence R. Stanberry, Richard Strugnell. (2011) Vaccines of the future. Perspectives in Vaccinology 1:1, 151-199
CrossRef23
Nirianne Marie Q. Palacpac, Nobuko Arisue, Takahiro Tougan, Ken J. Ishii, Toshihiro Horii. (2011) Plasmodium falciparum serine repeat antigen 5 (SE36) as a malaria vaccine candidate. Vaccine 29:35, 5837-5845
CrossRef24
B. Greenhouse, B. Ho, A. Hubbard, D. Njama-Meya, D. L. Narum, D. E. Lanar, S. Dutta, P. J. Rosenthal, G. Dorsey, C. C. John. (2011) Antibodies to Plasmodium falciparum Antigens Predict a Higher Risk of Malaria But Protection From Symptoms Once Parasitemic. Journal of Infectious Diseases 204:1, 19-26
CrossRef25
P. Bejon, J. Cook, E. Bergmann-Leitner, A. Olotu, J. Lusingu, J. Mwacharo, J. Vekemans, P. Njuguna, A. Leach, M. Lievens, S. Dutta, L. von Seidlein, B. Savarese, T. Villafana, M. M. Lemnge, J. Cohen, K. Marsh, P. H. Corran, E. Angov, E. M. Riley, C. J. Drakeley. (2011) Effect of the Pre-erythrocytic Candidate Malaria Vaccine RTS,S/AS01E on Blood Stage Immunity in Young Children. Journal of Infectious Diseases 204:1, 9-18
CrossRef26
Rino Rappuoli, Alan Aderem. (2011) A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 473:7348, 463-469
CrossRef27
M. T. White, J. T. Griffin, E. M. Riley, C. J. Drakeley, A. M. Moorman, P. O. Sumba, J. W. Kazura, A. C. Ghani, C. C. John. (2011) Efficacy model for antibody-mediated pre-erythrocytic malaria vaccines. Proceedings of the Royal Society B: Biological Sciences 278:1710, 1298-1305
CrossRef28
Jason A Regules, James F Cummings, Christian F Ockenhouse. (2011) The RTS,S vaccine candidate for malaria. Expert Review of Vaccines 10:5, 589-599
CrossRef29
Nathalie Garçon, Marcelle Van Mechelen. (2011) Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems. Expert Review of Vaccines 10:4, 471-486
CrossRef30
Christopher Palma, Michael G. Overstreet, Jean-Marc Guedon, Egbert Hoiczyk, Cameron Ward, Kasey A. Karen, Fidel Zavala, Gary Ketner. (2011) Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice. Vaccine 29:8, 1683-1689
CrossRef31
Brian Greenwood. (2011) Immunological correlates of protection for the RTS,S candidate malaria vaccine. The Lancet Infectious Diseases 11:2, 75-76
CrossRef32
Ally Olotu, John Lusingu, Amanda Leach, Marc Lievens, Johan Vekemans, Salum Msham, Trudie Lang, Jayne Gould, Marie-Claude Dubois, Erik Jongert, Preeti Vansadia, Terrell Carter, Patricia Njuguna, Ken O Awuondo, Anangisye Malabeja, Omar Abdul, Samwel Gesase, Neema Mturi, Chris J Drakeley, Barbara Savarese, Tonya Villafana, Didier Lapierre, W Ripley Ballou, Joe Cohen, Martha M Lemnge, Norbert Peshu, Kevin Marsh, Eleanor M Riley, Lorenz von Seidlein, Philip Bejon. (2011) Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial. The Lancet Infectious Diseases 11:2, 102-109
CrossRef33
J.O. Adebayo, A.U. Krettli. (2011) Potential antimalarials from Nigerian plants: A review. Journal of Ethnopharmacology 133:2, 289-302
CrossRef34
Johan Vekemans, Kevin Marsh, Brian Greenwood, Amanda Leach, William Kabore, Solange Soulanoudjingar, Kwaku Asante, Daniel Ansong, Jennifer Evans, Jahit Sacarlal, Philip Bejon, Portia Kamthunzi, Nahya Salim, Patricia Njuguna, Mary J Hamel, Walter Otieno, Samwel Gesase, David Schellenberg, . (2011) Assessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient care. Malaria Journal 10:1, 221
CrossRef35
Amanda Leach, Johan Vekemans, Marc Lievens, Opokua Ofori-Anyinam, Conor Cahill, Seth Owusu-Agyei, Salim Abdulla, Eusebio Macete, Patricia Njuguna, Barbara Savarese, Christian Loucq, W Ripley Ballou, . (2011) Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa. Malaria Journal 10:1, 224
CrossRef36
Marc Lievens, John J Aponte, John Williamson, Bruno Mmbando, Ali Mohamed, Philip Bejon, Amanda Leach. (2011) Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS,S/AS01 malaria vaccine in African children. Malaria Journal 10:1, 222
CrossRef37
Christine Swysen, Johan Vekemans, Myriam Bruls, Sunny Oyakhirome, Chris Drakeley, Peter Kremsner, Brian Greenwood, Opokua Ofori-Anyinam, Brenda Okech, Tonya Villafana, Terrell Carter, Barbara Savarese, Adriano Duse, Andrea Reijman, Charlotte Ingram, John Frean, Bernhards Ogutu, . (2011) Development of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine. Malaria Journal 10:1, 223
CrossRef38
Rachel A Smith, Victoria C Barclay, Jill L Findeis. (2011) Investigating preferences for mosquito-control technologies in Mozambique with latent class analysis. Malaria Journal 10:1, 200
CrossRef39
Muzamil Mahdi Abdel Hamid, Edmond J Remarque, Ibrahim M El Hassan, Ayman A Hussain, David L Narum, Alan W Thomas, Clemens HM Kocken, Walter R Weiss, Bart W Faber. (2011) Malaria infection by sporozoite challenge induces high functional antibody titres against blood stage antigens after a DNA prime, poxvirus boost vaccination strategy in Rhesus macaques. Malaria Journal 10:1, 29
CrossRef40
George Mtove, Ben Amos, Behzad Nadjm, Ilse CE Hendriksen, Arjen M Dondorp, Abraham Mwambuli, Deok Ryun Kim, R Leon Ochiai, John D Clemens, Lorenz von Seidlein, Hugh Reyburn, Jacqueline Deen. (2011) Decreasing incidence of severe malaria and community-acquired bacteraemia among hospitalized children in Muheza, north-eastern Tanzania, 2006-2010. Malaria Journal 10:1, 320
CrossRef41
Daniel Y. Bargieri, Irene S. Soares, Fabio T. M. Costa, Catarina J. Braga, Luis C. S. Ferreira, Mauricio M. Rodrigues. (2011) Malaria Vaccine Development: Are Bacterial Flagellin Fusion Proteins the Bridge between Mouse and Humans?. Journal of Parasitology Research 2011, 1-10
CrossRef42
Chandy C. John, Peter J. Krause. 2011. Malaria (Plasmodium). , 1198-1207.
CrossRef43
Joanna Chataway, Rebecca Hanlin, Julius Mugwagwa, Lois Muraguri. (2010) Global health social technologies: Reflections on evolving theories and landscapes. Research Policy 39:10, 1277-1288
CrossRef44
Peter D. Crompton, Susan K. Pierce, Louis H. Miller. (2010) Advances and challenges in malaria vaccine development. Journal of Clinical Investigation 120:12, 4168-4178
CrossRef45
J. Cohen, S. Benns, J. Vekemans, A. Leach. (2010) Le candidat vaccin antipaludique RTS,S/AS est entré en essais cliniques de phase III. Annales Pharmaceutiques Françaises 68:6, 370-379
CrossRef46
Alphonse Ouédraogo, Alfred B. Tiono, Amidou Diarra, Issa O. Nébié, Amadou T. Konaté, Sodiomon B. Sirima. (2010) The effects of a pre-season treatment with effective antimalarials on subsequent malaria morbidity in under five-year-old children living in high and seasonal malaria transmission area of Burkina Faso. Tropical Medicine & International Health 15:11, 1315-1321
CrossRef47
Danny A Milner. (2010) Rethinking cerebral malaria pathology. Current Opinion in Infectious Diseases 23:5, 456-463
CrossRef48
Alexander D. Douglas, Simone C. de Cassan, Matthew D.J. Dicks, Sarah C. Gilbert, Adrian V.S. Hill, Simon J. Draper. (2010) Tailoring subunit vaccine immunogenicity: Maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1. Vaccine 28:44, 7167-7178
CrossRef49
Blaise Genton, Valérie D’Acremont, Floriana Lurati-Ruiz, Daniele Verhage, Régine Audran, Cornelus Hermsen, Liselotte Wolters, Christophe Reymond, François Spertini, Robert Sauerwein. (2010) Randomized double-blind controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to protect against challenge with P. falciparum. Vaccine 28:40, 6573-6580
CrossRef50
Geert Leroux-Roels. (2010) Unmet needs in modern vaccinology. Vaccine 28, C25-C36
CrossRef51
Suman Mazumdar, Suraksha Sachdeva, Virander S. Chauhan, Syed Shams Yazdani. (2010) Identification of cultivation condition to produce correctly folded form of a malaria vaccine based on Plasmodium falciparum merozoite surface protein-1 in Escherichia coli. Bioprocess and Biosystems Engineering 33:6, 719-730
CrossRef52
Tracy M. Handel, Richard Horuk. (2010) Duffy antigen inhibitors: useful therapeutics for malaria?. Trends in Parasitology 26:7, 329-333
CrossRef53
M. Pinder, V.S. Moorthy, B.D. Akanmori, B. Genton, G.V. Brown. (2010) MALVAC 2009: Progress and Challenges in Development of Whole Organism Malaria Vaccines for Endemic Countries, 3–4 June 2009, Dakar, Senegal. Vaccine 28:30, 4695-4702
CrossRef54
Sofia Casares, Teodor-Doru Brumeanu, Thomas L. Richie. (2010) The RTS,S malaria vaccine. Vaccine 28:31, 4880-4894
CrossRef55
Joseph R. Fitchett, Mary K. Cooke. (2010) Genetically engineered parasites: the solution to designing an effective malaria vaccine?. Trends in Parasitology 26:7, 322-323
CrossRef56
M Lamine Mbow, Ennio De Gregorio, Nicholas M Valiante, Rino Rappuoli. (2010) New adjuvants for human vaccines. Current Opinion in Immunology 22:3, 411-416
CrossRef57
Hildegund CJ Ertl, Antonio Lanzavecchia. (2010) Introduction. Current Opinion in Immunology 22:3, 355-357
CrossRef58
P. D. Crompton, M. A. Kayala, B. Traore, K. Kayentao, A. Ongoiba, G. E. Weiss, D. M. Molina, C. R. Burk, M. Waisberg, A. Jasinskas, X. Tan, S. Doumbo, D. Doumtabe, Y. Kone, D. L. Narum, X. Liang, O. K. Doumbo, L. H. Miller, D. L. Doolan, P. Baldi, P. L. Felgner, S. K. Pierce. (2010) A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proceedings of the National Academy of Sciences 107:15, 6958-6963
CrossRef59
Daniel Y. Bargieri, Juliana A. Leite, Stefanie C.P. Lopes, Maria Elisabete Sbrogio-Almeida, Catarina J.M. Braga, Luis C.S. Ferreira, Irene S. Soares, Fabio T.M. Costa, Mauricio M. Rodrigues. (2010) Immunogenic properties of a recombinant fusion protein containing the C-terminal 19kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella Typhimurium. Vaccine 28:16, 2818-2826
CrossRef60
Aubrey J Cunnington, Eleanor M Riley. (2010) Suppression of vaccine responses by malaria: insignificant or overlooked?. Expert Review of Vaccines 9:4, 409-429
CrossRef61
A. L. Goodman, S. J. Draper. (2010) Blood-stage malaria vaccines — recent progress and future challenges. Annals of Tropical Medicine and Parasitology 104:3, 189-211
CrossRef62
Meral Esen. (2010) Assessment of humoral immune responses in malaria vaccine trials. Wiener klinische Wochenschrift 122:S1, 4-6
CrossRef63
Balwan Singh, Monica Cabrera-Mora, Jianlin Jiang, Mary Galinski, Alberto Moreno. (2010) Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate. Vaccine 28:14, 2580-2592
CrossRef64
Vasee S Moorthy, Marie Paule Kieny. (2010) Reducing empiricism in malaria vaccine design. The Lancet Infectious Diseases 10:3, 204-211
CrossRef65
Mark A. Pierce, Ruth D. Ellis, Laura B. Martin, Elissa Malkin, Eveline Tierney, Kazutoyo Miura, Michael P. Fay, Joanne Marjason, Suzanne L. Elliott, Gregory E.D. Mullen, Kelly Rausch, Daming Zhu, Carole A. Long, Louis H. Miller. (2010) Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults. Vaccine 28:10, 2236-2242
CrossRef66
Marjorie Makoni, Deepa Mukundan. (2010) Fever. Current Opinion in Pediatrics 22:1, 100-106
CrossRef67
Christian Loucq. (2010) Malaria vaccines: current situation, challenges and strategy for the future; a developer’s perspective from the PATH Malaria Vaccine Initiative. Therapy 7:1, 59-67
CrossRef68
RIMA F. KHABBAZ, STEPHEN M. OSTROFF, JAMES W. LeDUC, ROBIN MOSELEY, JAMES M. HUGHES. 2010. Emerging and Reemerging Infectious Disease Threats. , 199-219.
CrossRef69
Johan Vekemans, Amanda Leach, Joe Cohen. (2009) Development of the RTS,S/AS malaria candidate vaccine. Vaccine 27, G67-G71
CrossRef70
S. Pichyangkul, P. Tongtawe, U. Kum-Arb, K. Yongvanitchit, M. Gettayacamin, M.R. Hollingdale, A. Limsalakpetch, V.A. Stewart, D.E. Lanar, S. Dutta, E. Angov, L.A. Ware, E.S. Bergmann-Leitner, B. House, G. Voss, M.C. Dubois, J.D. Cohen, M.M. Fukuda, D.G. Heppner, R.S. Miller. (2009) Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys. Vaccine 28:2, 452-462
CrossRef71
Diadié Maïga, Bartholomew Dicky Akanmori, Liliana Chocarro. (2009) Joint reviews and inspections: Strategic forms of collaboration for strengthening the regulatory oversight of vaccine clinical trials in Africa. Vaccine 28:2, 571-575
CrossRef72
Ulrike Holzgrabe. (2009) Neue Hoffnung auf eine Malaria-Impfung. Pharmazie in unserer Zeit 38:6, 486-487
CrossRef73
Ariane Rodríguez, Ratna Mintardjo, Dennis Tax, Gert Gillissen, Jerome Custers, Maria Grazia Pau, Jaco Klap, Sampa Santra, Harikrishnan Balachandran, Norman L. Letvin, Jaap Goudsmit, Katarina Radošević. (2009) Evaluation of a prime-boost vaccine schedule with distinct adenovirus vectors against malaria in rhesus monkeys. Vaccine 27:44, 6226-6233
CrossRef74
B. GREENWOOD, G. TARGETT. (2009) Do we still need a malaria vaccine?. Parasite Immunology 31:9, 582-586
CrossRef75
C. SPEAKE, P. E. DUFFY. (2009) Antigens for pre-erythrocytic malaria vaccines: building on success. Parasite Immunology 31:9, 539-546
CrossRef76
Charlotte Schubert. (2009) Boosting our best shot. Nature Medicine 15:9, 984-988
CrossRef77
W. R. BALLOU. (2009) The development of the RTS,S malaria vaccine candidate: challenges and lessons. Parasite Immunology 31:9, 492-500
CrossRef78
Thomas E. Wellems, Karen Hayton, Rick M. Fairhurst. (2009) The impact of malaria parasitism: from corpuscles to communities. Journal of Clinical Investigation 119:9, 2496-2505
CrossRef79
Karin Loré, Gunilla B Karlsson Hedestam. (2009) Novel adjuvants for B cell immune responses. Current Opinion in HIV and AIDS 4:5, 441-446
CrossRef80
W. P. O’MEARA, T. LANG. (2009) Malaria vaccine trial endpoints - bridging the gaps between trial design, public health and the next generation of vaccines. Parasite Immunology 31:9, 574-581
CrossRef81
A. M. MOORMANN. (2009) How might infant and paediatric immune responses influence malaria vaccine efficacy?. Parasite Immunology 31:9, 547-559
CrossRef82
R. N. COLER, D. CARTER, M. FRIEDE, S. G. REED. (2009) Adjuvants for malaria vaccines. Parasite Immunology 31:9, 520-528
CrossRef83
Alicia Demirjian, Ofer Levy. (2009) Neonatal Vaccination. The Pediatric Infectious Disease Journal 28:9, 833-835
CrossRef84
Stephen Todryk, Philip Bejon. (2009) Malaria vaccine development: Lessons from the field. European Journal of Immunology 39:8, 2007-2010
CrossRef85
Ashraful Haque, Michael F Good. (2009) Malaria vaccine research: lessons from 2008/9. Future Microbiology 4:6, 649-654
CrossRef86
Roestenberg, Meta, McCall, Matthew, Hopman, Joost, Wiersma, JorienLuty, Adrian J.F., van Gemert, Geert Jan, van de Vegte-Bolmer, Marga, van Schaijk, Ben, Teelen, KarinaArens, TheoSpaarman, Lopke, de Mast, Quirijn, Roeffen, Will, Snounou, Georges, Rénia, Laurent, van der Ven, Andre, Hermsen, Cornelus C., Sauerwein, Robert, . (2009) Protection against a Malaria Challenge by Sporozoite Inoculation. New England Journal of Medicine 361:5, 468-477
Full Text87
M. Dinerman. (2009) Malaria in Children Following International Travel. AAP Grand Rounds 22:1, 8-8
CrossRef88
Philip Bejon, Salim Abdulla, John Lusingu, Ally Olotu, Amanda Leach, Marc Lievens, Marcel Tanner, Lorenz von Seidlein. (2009) Response to “Poor control vaccines in two randomised trials of malaria vaccine?”. Vaccine 27:35, 4745-4746
CrossRef89
Jack S Richards, James G Beeson. (2009) The future for blood-stage vaccines against malaria. Immunology and Cell Biology 87:5, 377-390
CrossRef90
Brian Opeskin. (2009) Malaria in Pacific populations: seen but not heard?. Journal of Population Research 26:2, 175-199
CrossRef91
Peter Aaby, Henrik Ravn, Christine S. Benn. (2009) Poor control vaccines in two randomised trials of malaria vaccine?. Vaccine 27:22, 2914-2915
CrossRef92
Ross L. Coppel. (2009) Vaccinating with the genome: a Sisyphean task?. Trends in Parasitology 25:5, 205-212
CrossRef93
Michael F. Good. (2009) The hope but challenge for developing a vaccine that might control malaria. European Journal of Immunology 39:4, 939-943
CrossRef94
Vasee Moorthy, Peter G Smith, Marie-Paule Kieny. (2009) A vaccine against malaria: a substantial step forward. The Lancet 373:9673, 1411-1412
CrossRef95
(2009) RTS,S/AS01E Vaccine against Malaria. New England Journal of Medicine 360:12, 1253-1254
Full Text96
Gloria Gonzalez-Aseguinolaza. (2009) Malaria vaccine: the latest news from RTS,S/AS01E vaccine. Expert Review of Vaccines 8:3, 285-288
CrossRef97
(2009) Research Highlights. Nature Medicine 15:1, 28-29
CrossRef98
(2009) News in brief. Nature Medicine 15:1, 6-7
CrossRef99
Nizar Ajjan. 2009. Acquisitions récentes en matière de vaccinations et vaccins du futur. , 207-301.
CrossRef100
Francis W. Muregi, Akira Ishih. (2009) Next-generation antimalarial drugs: hybrid molecules as a new strategy in drug design. Drug Development Researchn/a-n/a
CrossRef101
Collins, William E., Barnwell, John W., . (2008) A Hopeful Beginning for Malaria Vaccines. New England Journal of Medicine 359:24, 2599-2601
Full Text102
Brendan Maher. (2008) Malaria vaccine gets shot in the arm from tests. Nature 456:7223, 680-681
CrossRef
- Letters
